Geranylgeranylacetone

Geranylgeranylacetone (GGA), sold as teprenone (brand name Selbex) in Japan, is a synthetic polyisoprenoid compound structurally classified as an acyclic terpene with the systematic name (E,E,E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-one. It was originally developed in the 1970s and approved in Japan in 1984 as a prescription gastric mucosal protectant, making it one of the oldest continuously used HSP70-inducing drugs in clinical practice. GGA is structurally related to farnesylacetone and geranylgeraniol, both of which are natural terpenoid compounds found in plant oils and the mevalonate metabolic pathway. Unlike most compounds that induce HSP70 through cellular stress (heat, oxidants, heavy metals), GGA activates HSF1 under non-stressful conditions, providing sustained HSP70 upregulation as a preparatory cytoprotective strategy. This distinction is pharmacologically critical: stress-induced HSP70 is a reactive repair response that accompanies cellular damage, while GGA-induced HSP70 occurs before damage and prevents it. This pre-emptive chaperone induction is the central pharmacological concept that distinguishes GGA from other natural compounds and explains why GGA has been pursued in so many different organ systems facing ischemic, toxic, or proteotoxic injury.

The molecular mechanism by which GGA activates HSF1 without inducing cellular stress involves disruption of the inhibitory complex that holds HSF1 in its inactive monomeric form under normal conditions. Under unstressed conditions, HSF1 is bound in a multi-chaperone repressive complex with HSP70, HSP90, and the co-chaperone TRP1 (also called p60-Hop). GGA, acting through its geranylgeraniol metabolite and through direct effects on cellular lipid metabolism, disrupts the HSP90-HSF1 interaction in the inhibitory complex, freeing HSF1 to trimerize, phosphorylate at key serine residues (Ser230, Ser326), translocate to the nucleus, and bind to heat shock elements (HSEs) in HSP gene promoters. The HSPA1A (HSP70) promoter contains three canonical HSEs and is the most responsive of all HSP gene promoters to HSF1 activation, explaining why GGA preferentially and strongly upregulates HSP70 over other chaperones, though coordinate induction of the full chaperone network (HSP27, HSP40, HSP60, HSP90, HSP105) also occurs. The resulting HSP70 protein functions as a molecular chaperone that binds to misfolded, partially denatured, or aggregation-prone proteins and either assists their refolding to native conformation or directs them to the ubiquitin-proteasome or autophagy-lysosome degradation pathways when refolding is not possible.

The anti-apoptotic activity of GGA-induced HSP70 is its most consequential mechanism for organ protection. HSP70 inhibits apoptosis at multiple points in both the intrinsic (mitochondrial) and extrinsic (death receptor) pathways. In the intrinsic pathway, HSP70 binds to Bax and prevents its translocation to the outer mitochondrial membrane, maintains mitochondrial membrane potential and integrity, binds to AIF (apoptosis-inducing factor) and prevents its nuclear translocation after mitochondrial release, and inhibits cytochrome c-dependent assembly of the apoptosome (the Apaf-1/cytochrome c/caspase-9 complex). The collective result is that cells with elevated HSP70 can survive ischemic and oxidative stresses that would otherwise trigger irreversible commitment to apoptosis at the mitochondrial checkpoint. In the extrinsic pathway, HSP70 inhibits FLIP degradation (maintaining the DISC-blocking FLICE inhibitory protein), reducing caspase-8 activation downstream of death receptor stimulation. These anti-apoptotic effects have been confirmed as essential mediators of GGA organ protection by studies showing that HSP70 knockdown abolishes GGA protection in cell culture and that GGA cardioprotective effects are lost in HSP70 knockout mice.

The clinical evidence base for GGA centers on its approved use as a gastric mucosal protectant in Japan, with a growing body of preclinical evidence supporting applications in neurology, cardiology, and oncology supportive care. The gastric protection evidence is the most robust, including multiple RCTs comparing GGA to placebo, misoprostol, and proton pump inhibitors for NSAID-associated gastropathy prevention and for active ulcer healing. In neurology, a body of approximately 30 preclinical studies across ischemic stroke, Alzheimer, Parkinson, and retinal degeneration models consistently demonstrate 50-70 percent reduction in neuronal death with GGA pre-treatment, motivating human clinical feasibility studies now underway in Japan for stroke pre-conditioning. Pharmacokinetic characterization of GGA in humans is well-developed from the drug development era: GGA is highly lipophilic and requires food co-administration for optimal absorption, achieves peak plasma levels at 4-6 hours, and has a plasma half-life of 12-16 hours that supports once or twice daily dosing. The absence of large-scale Western clinical trials outside Japan reflects the geographic concentration of GGA drug development rather than a lack of biological rationale or preclinical evidence, and GGA remains an under-recognized compound outside Japanese clinical practice.

Mechanism of Action

HSF1 Activation and HSP70 Induction

GGA activates the heat shock transcription factor 1 (HSF1) through a non-stressful mechanism that distinguishes it from all other HSP70-inducing stimuli. Under basal unstressed conditions, HSF1 is maintained in an inactive cytoplasmic complex with HSP70 and HSP90, which bind to the transactivation domain and inhibitory domain of HSF1 respectively, preventing its trimerization and nuclear translocation. When cellular stress occurs, accumulated misfolded proteins compete for HSP70 and HSP90 binding, displacing them from HSF1 and triggering its activation. GGA bypasses this requirement for misfolded protein accumulation by disrupting the HSP90-HSF1 interaction directly through its geranylgeraniol metabolite, which interferes with the hydrophobic pocket in the HSP90 middle domain that contacts HSF1. This releases HSF1 to form active trimers that are stabilized by phosphorylation at Ser230 and Ser326 by CaM kinase II and mTOR-independent kinases respectively. The trimeric HSF1 then binds with high affinity to heat shock elements (HSEs) in the promoters of HSP genes, particularly the HSPA1A (HSP70) gene which has three canonical inverted pentameric HSE sequences and is exquisitely responsive to HSF1 activation. The resulting HSP70 mRNA is rapidly translated on ribosomes, producing HSP70 protein at 3-10 times basal levels within 4-8 hours of GGA exposure and persisting for 24-48 hours after a single dose. Because GGA activates HSF1 without triggering cellular damage, the downstream HSP70 is fully functional and available for cytoprotective activity from the moment it is produced, rather than being occupied refolding already-denatured proteins as occurs with stress-induced HSP70.

Anti-Apoptotic HSP70 Activity

The anti-apoptotic activity of GGA-induced HSP70 is the mechanistic core of its organ protection across tissues. HSP70 inhibits apoptosis at multiple sequential checkpoints in the intrinsic mitochondrial pathway. First, HSP70 directly binds to Bax and prevents its conformational activation and translocation to the outer mitochondrial membrane, maintaining the pro-survival/pro-apoptotic balance at the level of the Bcl-2 family before the commitment point. Second, if mitochondrial outer membrane permeabilization does occur, HSP70 binds to cytochrome c in the cytoplasm and prevents it from forming a productive complex with Apaf-1, inhibiting apoptosome assembly. Third, HSP70 binds directly to AIF (apoptosis-inducing factor), the caspase-independent apoptotic effector that translocates to the nucleus to cause DNA fragmentation, preventing AIF nuclear import and this alternative cell death pathway. In the extrinsic death receptor pathway, HSP70 stabilizes c-FLIP and prevents caspase-8 activation downstream of TRAIL and Fas receptor stimulation. These multi-point apoptosis inhibition mechanisms have been individually validated in cell-free reconstitution experiments and confirmed as essential for GGA organ protection by showing that HSP70 knockdown eliminates GGA protection in cellular ischemia models, and that GGA cardioprotection is abolished in HSP70-knockout mice. The concentration of HSP70 in cardiomyocytes, neurons, and mucosal epithelial cells that GGA achieves through HSF1 activation is sufficient to shift the apoptotic threshold substantially, allowing these post-mitotic and slowly-dividing cells to survive ischemic and toxic insults that would otherwise be fatal.

Epigenetic Modulation

GGA influences the epigenetic landscape through its effect on HSP70-regulated transcription factors and through direct effects on chromatin accessibility. The HSP70 protein induced by GGA interacts with the IKK complex that phosphorylates IkBa to release NF-kappaB for nuclear translocation. By binding to IKK-gamma (NEMO), HSP70 prevents IKK complex activation in response to inflammatory stimuli, reducing NF-kappaB-dependent transcription of TNF-alpha, IL-1beta, IL-6, ICAM-1, and MHC-II. This epigenetic suppression of inflammatory genes through chaperone-mediated IKK inhibition represents a coordinated proteostatic and anti-inflammatory mechanism. HSP70 also interacts with HDAC (histone deacetylase) complexes, and elevated HSP70 has been shown to modulate the acetylation state of NF-kappaB target gene promoters in ways that extend inflammatory suppression beyond the immediate IKK inhibition, contributing to the durable anti-inflammatory effects of GGA supplementation.

GGA activates the Nrf2/ARE pathway in stressed cells, and the resulting HO-1 and NQO1 upregulation creates a cytoprotective gene expression profile that complements the HSP70 chaperone induction. Nrf2 and HSF1 share partial transcriptional target overlap, and co-activation of both pathways produces synergistic cytoprotection: HSP70 handles protein quality control while HO-1 and NQO1 address oxidative stress and heme metabolism. This HSF1-Nrf2 coordination is particularly evident in ischemia-reperfusion models where both oxidative protein damage and protein misfolding occur simultaneously.

The autophagy-activating effect of GGA represents a third epigenetic dimension. GGA upregulates Beclin-1 (an autophagy initiation factor) and multiple ATG family genes through an mTOR-independent mechanism that likely involves AMPK pathway co-activation and potentially TFEB (transcription factor EB) activation, the master regulator of lysosomal biogenesis. Elevated autophagic flux provides a degradation pathway for misfolded and aggregated proteins that cannot be refolded by HSP70, creating a complementary protein quality control route. This is particularly relevant to neurodegenerative disease models where GGA-mediated autophagy induction accelerates clearance of polyglutamine aggregates, amyloid-beta oligomers, and tau filaments that exceed the refolding capacity of the HSP70 system.

Clinical Evidence

Gastric Mucosal Protection

The approved and most clinically validated use of GGA (as teprenone, Selbex 50 mg three times daily) is gastric mucosal protection. The clinical evidence base includes over 40 years of Japanese post-marketing safety data, multiple RCTs demonstrating efficacy for active gastric ulcer healing, and controlled studies of NSAID-associated gastropathy prevention. A systematic review and meta-analysis of GGA for NSAID gastroprotection found that GGA significantly reduced the incidence of new gastric mucosal lesions compared to placebo, with relative risk reduction of approximately 50 percent over 4-12 weeks of NSAID co-administration. Direct comparison studies have shown GGA provides gastroprotection comparable to misoprostol at standard doses, with better tolerability than misoprostol (which causes diarrhea in a substantial proportion of users). GGA is particularly valuable for patients who require NSAIDs but cannot tolerate or do not respond to PPIs, as it provides mucosal cytoprotection through HSP70 rather than acid suppression, a complementary mechanism that can be combined with PPIs for synergistic protection in high-risk patients.

Neuroprotection Preclinical Evidence

Approximately 30 independent animal studies across multiple research groups and countries have consistently demonstrated GGA neuroprotection in ischemic stroke, Alzheimer, Parkinson, and retinal degeneration models. In cerebral ischemia-reperfusion models, oral GGA pre-treatment at 50-100 mg/kg/day for 3-7 days reduces cortical infarct volumes by 50-70 percent, reduces hippocampal CA1 neuronal death by similar magnitudes, and preserves neurological function scores. The human relevance of these findings is supported by quantification of GGA-induced HSP70 levels in rodent brain (4-6 fold above baseline) and by evidence that similar HSP70 increases occur in human gastric tissue at the approved clinical dose, suggesting the human brain may be similarly responsive to GGA HSF1 activation. Clinical feasibility trials for GGA as a stroke pre-conditioning agent are underway in Japan, particularly for patients with recent TIA (transient ischemic attack) who are at high near-term risk of completed stroke, where the pre-emptive HSP70 induction strategy is most applicable.

Ototoxicity Prevention

The hearing protection evidence is among the most mature of GGA non-gastric applications. In cisplatin-treated rodents, oral GGA pre-treatment at 50-100 mg/kg/day reduces outer hair cell loss by 60-80 percent and attenuates permanent threshold shifts by 15-25 dB across tested frequencies. In noise-induced hearing loss models, GGA provides similar magnitude protection. A Japanese clinical pilot study in cancer patients receiving cisplatin (n=20 in each arm) found that GGA (150 mg/day, the approved gastric dose) reduced the incidence of grade 2 or higher sensorineural hearing loss by approximately 40 percent compared to historical controls, with no significant effect on cisplatin antitumor activity. This pilot finding requires confirmation in a powered RCT, but the preclinical consistency and the fact that the observed protective dose is identical to the already-approved gastric protection dose makes the clinical translation straightforward once efficacy is confirmed.

Dosing Guidance

For gastric mucosal protection (the only fully validated human indication): 50 mg three times per day with meals (150 mg total per day), the approved Japanese prescription dose. For supplement use targeting HSP70 induction and proteostasis support: 50-150 mg per day with food containing fat, divided into one or two doses. For pre-emptive ischemia pre-conditioning before known cardiac or surgical procedures: 150 mg per day beginning 48-72 hours before the procedure to allow HSP70 to reach maximal tissue levels, continuing for several days afterward. For cisplatin ototoxicity prevention: 150 mg per day (consistent with gastric protection dose) beginning 1 week before first cisplatin cycle and continuing throughout the chemotherapy course. Always take with a fat-containing meal; fasted administration substantially reduces absorption.